NEW YORK, January 15, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Endocyte, Inc. (NASDAQ :ECYT ), PharMerica Corporation (NYSE :PMC ), Synta Pharmaceuticals Corp. (NASDAQ :SNTA ), AtriCure, Inc. (NASDAQ :ATRC ), and Cytokinetics, Incorporated (NASDAQ :CYTK ). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Endocyte, Inc. Research Report
On January 10, 2014, Endocyte, Inc.'s (Endocyte) stock ended the day at $14.02, compared to the previous closing price at $10.90, representing a significant 28.62% growth. The Company's stock grew 28.04% over the past three trading days, compared to the Dow Jones Industrial Average Index which declined 0.57% during the same period. The Full Research Report on Endocyte, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
PharMerica Corporation Research Report
On January 10, 2014, PharMerica Corp. (PharMerica) announced that it has completed acquisition of BGS Pharmacy Partners Inc. (BGS) in an all-cash transaction. Greg Weishar, PharMerica's CEO, stated, "The transaction increases our presence in two important markets where we have existing operations, Las Vegas and Salt Lake City, and expands our geographic footprint in the Reno area. BGS has a talented team and has built a strong business based on patient care, clinical expertise, and customer service. We look forward to working with BGS' outstanding client base to serve the needs of their residents." The Company informed that it expects the acquisition to be accretive to its earnings in 2014. The Full Research Report on PharMerica Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Synta Pharmaceuticals Corp. Research Report
On January 9, 2014, Synta Pharmaceuticals Corp. (Synta) announced the initiation of three multicenter, randomized Phase II/III Trials, evaluating ganetespib in combination with chemotherapy in first-line treatment of patients with AML and high risk MDS. According to the Company, preclinical results from Synta and its collaborators, Alan K. Burnett of Cardiff University and Sanjay Bansal of the UT Health Science Center at San Antonio, have shown that ganetespib inhibits a number of cancer-promoting factors believed to contribute to the proliferation of leukemic cells and renders them more vulnerable to treatment with chemotherapy. "The selection of ganetespib for three major potentially registration-enabling trials in AML is an exciting validation of the clinical potential of ganetespib, and reinforces our strategy of continuing to expand the depth and breadth of the ganetespib program through collaborations with strong groups of investigators," said Safi R. Bahcall, Ph.D., President and CEO of Synta. "Promising preclinical and early clinical results have been observed with ganetespib and other Hsp90 inhibitors in AML. We are pleased by the decision of the Leukemia & Lymphoma Research Fund, the Cancer Research UK, and the trial investigators to invest in moving ganetespib forward into three large, randomized trials, which we hope will ultimately lead to new options for patients with this devastating disease." The Full Research Report on Synta Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
AtriCure, Inc. Research Report
On January 2, 2014, AtriCure, Inc. (AtriCure) announced the completion of the previously announced acquisition of Endoscopic Technologies, Inc. (Estech). Mike Carrel, President and CEO of AtriCure, said, "We are pleased to complete the acquisition of Estech, and we welcome the team to AtriCure. This transaction provides substantial benefits to AtriCure and strengthens our leadership position in the atrial fibrillation market; we are excited about the opportunities that our combined businesses will bring to our customers." AtriCure informed that it expects the transaction to increase sales and marketing expense as well as research and development expenditures in order to accelerate clinical development and commercial sales of the combined product portfolio. AtriCure further expects the transaction to be dilutive to earnings in 2014 and accretive in 2015 and beyond. The Full Research Report on AtriCure, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Cytokinetics, Incorporated Research Report
On January 10, 2014, Cytokinetics, Inc.'s (Cytokinetics) stock ended the day at $9.58, compared to the previous closing price at $8.35, representing a 14.73% growth. The Company's stock grew 22.51% over the past three trading days, compared to the Dow Jones Industrial Average Index which declined 0.57% over the same trading period. The Full Research Report on Cytokinetics, Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner